This company listing is no longer active
Oxford Cannabinoid Technologies Holdings Management
Management criteria checks 1/4
Oxford Cannabinoid Technologies Holdings' CEO is Clarissa Sowemimo-Coker, appointed in Dec 2022, has a tenure of 1.5 years. total yearly compensation is £215.67K, comprised of 90% salary and 10% bonuses, including company stock and options. directly owns 0.23% of the company’s shares, worth €3.38K. The average tenure of the management team and the board of directors is 1.5 years and 2.2 years respectively.
Key information
Clarissa Sowemimo-Coker
Chief executive officer
UK£215.7k
Total compensation
| CEO salary percentage | 90.0% |
| CEO tenure | 1.5yrs |
| CEO ownership | 0.2% |
| Management average tenure | 1.5yrs |
| Board average tenure | 2.2yrs |
Recent management updates
Recent updates
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Oct 31 2023 | n/a | n/a | -UK£4m |
| Jul 31 2023 | n/a | n/a | -UK£5m |
| Apr 30 2023 | UK£216k | UK£194k | -UK£6m |
| Apr 30 2022 | UK£194k | UK£174k | -UK£5m |
| May 31 2021 | n/a | n/a | -UK£3m |
Compensation vs Market: Clarissa's total compensation ($USD274.44K) is below average for companies of similar size in the German market ($USD409.23K).
Compensation vs Earnings: Clarissa's compensation has increased whilst the company is unprofitable.
CEO
Clarissa Sowemimo-Coker (44 yo)
1.5yrs
Tenure
UK£215,669
Compensation
Ms. Clarissa Ann Sowemimo-Coker serves as Chief Executive Officer at Oxford Cannabinoid Technologies Holdings Plc since April 12, 2023 and is its Executive Director since February 4, 2021. She was its Comp...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 1.5yrs | UK£215.67k | 0.23% € 3.4k | |
| Co-Founder & Non-Executive Director | no data | UK£25.00k | 1.96% € 28.9k | |
| Finance Director & Executive Director | 1.7yrs | UK£155.16k | no data | |
| Chief Scientific Officer | 3.9yrs | no data | no data | |
| General Counsel & Company Secretary | 1.5yrs | no data | 0.030% € 448.1 | |
| Executive Director & Chief Medical Officer | less than a year | no data | no data |
1.5yrs
Average Tenure
51yo
Average Age
Experienced Management: 0CB's management team is not considered experienced ( 1.5 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| CEO & Executive Director | 3.3yrs | UK£215.67k | 0.23% € 3.4k | |
| Co-Founder & Non-Executive Director | 3.3yrs | UK£25.00k | 1.96% € 28.9k | |
| Finance Director & Executive Director | 1.7yrs | UK£155.16k | no data | |
| Executive Director & Chief Medical Officer | less than a year | no data | no data | |
| Independent Non-Executive Chair | 3.2yrs | UK£45.00k | 0.060% € 880.0 | |
| Member of Scientific Advisory Board | 2.2yrs | no data | no data | |
| Senior Independent Non-Executive Director | 3.2yrs | UK£25.00k | no data | |
| Member of Scientific Advisory Board | 2.2yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.2yrs | no data | no data | |
| Independent Non-Executive Director | less than a year | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data |
2.2yrs
Average Tenure
51yo
Average Age
Experienced Board: 0CB's board of directors are not considered experienced ( 2.2 years average tenure), which suggests a new board.
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/06/07 08:31 |
| End of Day Share Price | 2024/06/06 00:00 |
| Earnings | 2023/10/31 |
| Annual Earnings | 2023/04/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Oxford Cannabinoid Technologies Holdings Plc is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Soo Romanoff | Edison Investment Research |